AIB 2012 Conference Proceedings - Academy of International ...
AIB 2012 Conference Proceedings - Academy of International ...
AIB 2012 Conference Proceedings - Academy of International ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
SUNDAY<br />
Building on scholarly assessments <strong>of</strong> extant measures <strong>of</strong> firm internationalization, this paper proposes an<br />
alternative measure grounded in transaction cost and internalization theories <strong>of</strong> international business. The<br />
proposed <strong>International</strong>ization Coefficient (IC) is designed to address the major issues <strong>of</strong> the most common<br />
measures, and suggested as a more robust operationalization <strong>of</strong> the concept <strong>of</strong> internationalization in theory.<br />
Implications on empirical international business research and potential contributions to theory testing and<br />
development are discussed. (For more information, please contact: Sandra Seno Alday, University <strong>of</strong> Sydney,<br />
Australia: sandra.seno-alday@sydney.edu.au)<br />
The Location and Co-Evolutionary Dynamics <strong>of</strong> Multi-National Enterprise in the Global Knowledge Economy<br />
Brian Hilton, Nottingham University Business School<br />
It is argues that the life cycle <strong>of</strong> technological cluster location is effected by the needs <strong>of</strong> design and<br />
governance in the value chain <strong>of</strong> Buckley's "Global Factory" This is sometimes not within Multi-National<br />
(Corporate) Enterprises (MNEs) but within networks <strong>of</strong> Multi-National Enterprise (MNE). <strong>International</strong> location is<br />
within the ambit <strong>of</strong> co-evolving institutions not just global ownership structures. This managerial fragmentation<br />
in the MNE value suggests that IB needs a frame <strong>of</strong> reference going beyond trade and FDI encompassing the<br />
location <strong>of</strong> knowledge creation in design cluster and supply chain value governance permitting those owning<br />
marketing (brand) equity to situate where they can best realise their equity. We argue that these two high<br />
value adding activities seem to locate in what North describes as Open Access Order (developed) societies that<br />
facilitates this, the new economic geographer's "North" and not in Local Access Orders (underdeveloped )<br />
societies, the "South", which do not. The theory developed is tested against the experience <strong>of</strong> the textile and<br />
garment industry where it is clear location occurs over periods far longer than the long run <strong>of</strong> capital flow but<br />
the even longer runs when technology and even the institutions <strong>of</strong> governance move. (For more information,<br />
please contact: Brian Hilton, Nottingham University Business School, China: brian.hilton@nottingham.edu.cn)<br />
Session: 1.4.13 - Interactive<br />
Track: 6 - Innovation and Knowledge Mgmt.<br />
Innovation in Emerging Economies<br />
Presented On: July 1, <strong>2012</strong> - 14:30-15:45<br />
Chair: Sheila M. Puffer, Northeastern University<br />
A Comparative Analysis <strong>of</strong> Innovation Outsourcing to China and India: The Location <strong>of</strong> Clinical Trials<br />
Klaus Nielsen, Birkbeck, University <strong>of</strong> London<br />
Tariq Malik, Dongbei University <strong>of</strong> Finance & Economics<br />
This study explores the reasons why foreign pharmaceutical firms prefer China rather than India as their<br />
location for innovation activities. We use clinical trials as the innovation activity and empirically compare the two<br />
locations with evidence for 2010 and 2011. Based on 1185 observations in two countries, we find that China is<br />
obviously the preferred choice and is increasingly becoming so. Large firms in particular tend to prefer China.<br />
European firms have relatively a higher preference for China as the location for clinical trials compared to<br />
American companies. Relatively small firms prefer India. The clinical trials in India are at earlier stages<br />
compared to the trials located in China which are typically at later stages. It appears that firms in China have<br />
entered earlier than those who locate in India for clinical trials. The paper discusses some possible explanations<br />
and suggests some implications. (For more information, please contact: Klaus Nielsen, Birkbeck, University <strong>of</strong><br />
London, United Kingdom: k.nielsen@bbk.ac.uk)<br />
<strong>AIB</strong> <strong>2012</strong> <strong>Conference</strong> <strong>Proceedings</strong><br />
Page 70